Home Primary Antibodies Anti-GLP-1 Mouse Antibody [B23D23] For research use only.

Anti-GLP-1 Mouse Antibody [B23D23]

Catalog No.: F1621

    Application: Reactivity:
    • Immunohistochemical analysis of formalin fixed paraffin embedded human pancreas tissue with F1621 at 1:500 dilution.

    Usage Information

    Dilution
    1:2000
    Application
    IHC, sELISA
    Reactivity
    Mouse, Human
    Source
    Mouse
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Positive Control Human pancreas tissue; Diabetic mice pancreas tissue
    Negative Control

    Exprimental Methods

    IHC
    Experimental Protocol：
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    Biological Description

    Specificity
    GLP-1 Mouse mAb recognizes endogenous levels of total GLP-1 protein.
    Subcellular Location
    Secreted
    Uniprot ID
    P01275
    Clone
    B23D23
    Synonym(s)
    Pro-glucagon, GCG
    Background
    Glucagon-like peptide-1 (GLP-1) is a 30-amino-acid incretin hormone primarily secreted by intestinal L-cells in response to nutrient ingestion, produced through the enzymatic cleavage of the proglucagon precursor. GLP-1 contains a conserved N-terminal sequence critical for receptor activation, including key residues such as His7 that are essential for binding and signaling, and adopts α-helical conformations stabilizing its interaction with the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor expressed in pancreatic β-cells, brain, gastrointestinal tract, and other tissues. Upon binding GLP-1R, the receptor activates G-proteins that stimulate adenylate cyclase, increasing intracellular cAMP, which triggers downstream effectors like protein kinase A (PKA) and Epac2, enhancing glucose-dependent insulin secretion, inhibiting glucagon release mainly via somatostatin secretion from δ-cells, and slowing gastric emptying to control postprandial glucose levels. GLP-1 also reduces appetite and promotes satiety via central nervous system pathways. GLP-1R activation exerts neuroprotective effects by modulating inflammation and promoting neuronal survival through cAMP/PKA and ERK signaling pathways. Additionally, GLP-1 influences mitochondrial function and energy metabolism in muscle and neuronal cells and favors bone formation by modulating the osteoprotegerin (OPG)/RANKL ratio to support skeletal health. Endogenously, GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), limiting its half-life to about 1–2 minutes, prompting the development of GLP-1 receptor agonists and DPP-4 inhibitors as therapeutics for type 2 diabetes and obesity.
    References
    • https://pubmed.ncbi.nlm.nih.gov/21950636/
    • https://pubmed.ncbi.nlm.nih.gov/39289339/

    Tech Support

    Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

    Handling Instructions

    Tel: +1-832-582-8158 Ext:3
    If you have any other enquiries, please leave a message.

    * Indicates a Required Field

    Please enter your name.
    Please enter your email. Please enter a valid email address.
    Please write something to us.